Corbus Pharmaceuticals Holdings Inc
CRBP - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$81.62M
Close$
$2.02
48.5% downside
Current Fair Value
48.5% downsideOvervalued by 48.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $81.62 Million |
|---|---|
| Enterprise Value | $62.51 Million |
| Earnings per Share | $-5.9 |
| Beta | 2.63 |
| Outstanding Shares | 19,407,688 |
Return
| Return on Equity | -99.67% |
|---|---|
| Return on Assets | -80.25% |
| Return on Invested Capital | -22.91% |
Valuation & Multiples
| P/E Ratio | -0.65 |
|---|---|
| PEG | -0.66 |
| Price to Sales | - |
| Price to Book Ratio | 0.78 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.59 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-1.26
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-1.27
Consensus analyst estimateRevenue Estimate
$1.67 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Corbus Pharmaceuticals Holdings, Inc.
28 employees
CEO: Dr. Yuval Cohen Ph.D.
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid...